Catherine Campbell

Catherine Campbell completed her PhD in neuroscience at the University of British Columbia. She has over 18 years of experience working in the biotechnology industry, including 16 years in Regulatory Affairs. Catherine previously worked at Allon Therapeutics and BioMarin Pharmaceuticals, before joining 4D Molecular Therapeutics in 2019, where she leads the regulatory department. She has worked on the development of several products including small molecules, biologics, gene therapies and combination products, at both clinical and commercial stages, and within various therapeutics areas.